

# ABG SUNDAL GOLLIER

# Sectra

# Dependable operating delivery

- Pace of cloud implementation to accelerate
- · Minor EBIT estimate upgrades
- We raise our TP to SEK 300 (275), implying nearly 20% upside

#### Do not fully extrapolate Q1 beat

Q1 beat on nearly all line items. Order intake was down ~80% y-o-y, but that is explained by a large, USD 227m contract that was booked in the comparison period. Adjusting for that, the order intake was approximately flat y-o-y. During the conference call, management made it clear that Sectra's cloud implementation capability must increase. The current pace of implementation is at least two hospitals per month, but the current pipeline of cloud orders means that the number would have to increase significantly. Our understanding, based on previous commentary, is that this capacity would have to at least triple from the current level. Therefore, additional capacity-increasing investments (i.e., higher opex) should be expected.

#### Minor estimate changes

We raise FY'25e-'26e EBIT by 4-2% on the back of the report. We have lowered our gross margin assumptions by 2pp due to a higher share of implementation-related (non-recurring) revenues that we believe will persist as cloud revenue ramps up. We remind investors that the current and the historical pace of hiring both indicate that Sectra is likely set to close a large Sectra One Cloud deal, most likely in North America.

# Outperformance warrants closing of discount to Pro Medicus

We reiterate our BUY recommendation and raise our target price to SEK 300 (275) per share, indicating a run-rate NTM EBIT multiple of  $\sim$ 52x (for a period with low growth and low margins), which represents a  $\sim$ 20% discount to key peer and competitor Pro Medicus.

#### Reason: Post-results comment

BUY HOLD SELL

#### IT

Estimate changes (%)

	2025e	2026e	2027e
Sales	0.5	0.4	0.2
EBIT	4.1	1.9	0.5
EPS	2.4	1.1	0.0
Source: ABG Sundal Collier			

#### SECT.B-SE/SECTB SS

Share price (SEK)	5/9/2024	255.40
Target price	(275.0)	300.0
MCap (SEKm)		47,210
MCap (EURm)		3,861
No. of shares (m)		181.0
Free float (%)		71.9
Av. daily volume (k)		66

Next event Q2 Report 12 December 2024

#### **Performance**



Analyst(s): nikola.kalanoski@abgsc.se, +46 8 566 286 04 daniel.thorsson@abgsc.se, +46 8 566 286 82

Source: ABG Sundal Collier, Company Data

SEKm	2023	2024	2025e	2026e	2027e
Sales	2,351	2,964	3,175	3,731	4,197
EBITDA	548	622	693	949	1,128
EBITDA margin (%)	23.3	21.0	21.8	25.4	26.9
EBIT adj.	393	505	601	840	1,012
EBIT adj. margin (%)	16.7	17.0	18.9	22.5	24.1
Pretax profit	479	553	608	874	1,065
EPS	1.95	2.22	2.49	3.58	4.37
EPS adj.	1.71	2.19	2.56	3.61	4.38
Sales growth (%)	20.6	26.1	7.1	17.5	12.5
EPS growth (%)	19.1	14.2	12.2	43.6	21.9

	2025e	2026e	2027e
P/E (x)	102.4	71.3	58.5
P/E adj. (x)	99.6	70.8	58.3
P/BVPS (x)	26.71	21.56	17.36
EV/EBITDA (x)	69.6	50.4	42.0
EV/EBIT adj. (x)	80.2	57.0	46.8
EV/sales (x)	15.19	12.83	11.29
ROE adj. (%)	29.0	33.8	33.0
Dividend yield (%)	0.5	0.6	0.6
FCF yield (%)	0.6	1.3	1.6
Le. adj. FCF yld. (%)	0.5	1.3	1.6
Net IB debt/EBITDA (x)	-1.4	-1.4	-1.6
Le. adj. ND/EBITDA (x)	-1.5	-1.5	-1.7

# **Company description**


Sectra is a leading provider of medical imaging software for the healthcare industry and a provider of secure communications solutions. The company has three groupwide financial goals over a rolling five-year period: (i) equity ratio of at least 30%, (ii) EBIT margin of at least 15% and (iii) at least 50% EBIT growth. Once all goals have been met, the company's primary goal shifts to earnings growth.

#### Sustainability information

# Sales and y-o-y growth 4,500 4,000 3,500 3,500 3,500 3,500 3,500 4,197 26% 3,731 4,197 25% 3,731 15% 15% 15% 15% 15% 15% 10% 5% 10% 5% 10% 5% 5% 5% 0% 5% 5% 5% 5% 5% 5% 5% 5% 5% 5% 5%


Source: ABG Sundal Collier, Company data.

### **EBIT and EBIT margin**



Source: ABG Sundal Collier, Company data.

# **Dividend and DPS**



Source: ABG Sundal Collier, Company data.

Footnote: Dividend cash flow lags the DPS figure by one year.

# **Risks**


Risks include but are not limited to: (i) Technological changes within Imaging IT, (ii) tightening of regulatory requirements for the handling of patient data, (iii) inability to successfully execute on large orders and (iv) security incidents that would harm the company's brand and reputation.

#### Order bookings and y-o-y growth




Source: ABG Sundal Collier, Company data

#### Free cash flow and cash conversion



Source: ABG Sundal Collier, Company data.

#### Segment sales



Source: ABG Sundal Collier, Company data.

# Financials and estimates

Below, we provide granular historical figures and estimates at the segment level, based on the company's reporting standards and habits:

# Key group financials

Group-level key financials ar	nd ratios												
				Quarte	•						Annual data		
SEKm	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25e	Q3'25e	Q4'25e	FY2023	FY2024	FY2025e	FY2026e	FY2027e
Key financials													
Contracted order bookings	2,970	503	1,854	897	615	750	750	850	4,636	6,224	2,965	4,150	5,350
o/w guaranteed orders	344	460	1,653	762	543	700	650	800	2,607	3,219	2,693	3,200	3,600
Net sales	584	788	694	898	724	756	756	938	2,351	2,964	3,175	3,731	4,197
EBIT	69	177	74	197	100	118	110	260	456	518	589	837	1,012
FX adj. EBIT	61	169	75	194	100	129	110	262	393	499	601	840	1,012
Pre-tax profit	77	190	73	212	101	123	115	268	479	553	608	874	1,065
Net profit	62	151	58	158	80	97	91	212	375	428	481	690	841
EPS	0.32	0.78	0.30	0.82	0.42	0.51	0.47	1.10	1.95	2.22	2.49	3.58	4.37
Ratios and other KPIs													
Total growth y-o-y	21%	40%	20%	24%	24%	-4%	9%	4%	21%	26%	7%	18%	12%
Organic growth y-o-y	14%	36%	20%	23%	25%	-1%	9%	5%	13%	24%	8%	18%	12%
FX y-o-y	6%	4%	0%	1%	-1%	-3%	0%	0%	8%	2%	-1%	0%	0%
M&A y-o-y	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Recurring revenue	397	430	435	464	482	500	515	544	1,360	1,725	2,040	2,400	2,770
o/w cloud recurring rev.	86	93	103	114	123	133	148	164	255	<i>397</i>	568	803	1,103
Non-recurring revenue	187	358	259	435	242	257	242	395	991	1,239	1,135	1,331	1,427
EBIT margin	11%	22%	10%	22%	13%	15%	14%	27%	19%	17%	18%	22%	24%
Adj. EBIT margin	10%	21%	11%	21%	14%	17%	14%	27%	16%	16%	19%	22%	24%
EBIT growth y-o-y	8%	64%	-15%	0%	44%	-33%	48%	32%	19%	14%	14%	42%	21%
Adj. EBIT growth y-o-y	-5%	57%	-14%	-2%	45%	-27%	48%	33%	3%	9%	16%	43%	21%
Average FTEs	1,112	1,127	1,150	1,171	1,222	1,242	1,262	1,282	1,056	1,171	1,282	1,362	1,442
ROIC	62%	56%	59%	64%	50%	40%	44%	49%	90%	64%	49%	60%	68%
ROCE	27%	33%	30%	27%	27%	26%	26%	26%	28%	27%	26%	31%	30%
ROE	30%	36%	34%	30%	29%	27%	28%	28%	32%	30%	28%	33%	33%

Source: ABG Sundal Collier, Company data.

Our annual estimate revisions are summarised below:

# **Annual estimate changes**

		Old estimates	i		New estimates	;	Pe	rcentage char	ige
SEKm	FY2025e	FY2026e	FY2027e	FY2025e	FY2026e	FY2027e	FY2025e	FY2026e	FY2027e
Net sales	3,159	3,717	4,186	3,175	3,731	4,197	1%	0%	0%
Total revenue	3,225	3,787	4,260	3,240	3,801	4,271	0%	0%	0%
Gross profit	2,870	3,370	3,792	2,812	3,307	3,715	-2%	-2%	-2%
EBITDA	669	934	1,123	693	949	1,128	4%	2%	0%
Adj. EBITDA	688	936	1,123	705	952	1,128	3%	2%	0%
EBIT	565	822	1,007	589	837	1,012	4%	2%	0%
FX adj. EBIT	584	824	1,007	601	840	1,012	3%	2%	0%
Total growth	6.6%	17.6%	12.6%	7.1%	17.5%	12.5%	0.5p.p.	-0.1p.p.	-0.2p.p.
Organic growth	8.0%	18.1%	12.6%	8.1%	17.8%	12.5%	0.1p.p.	-0.2p.p.	-0.2p.p.
Gross margin	89.0%	89.0%	89.0%	86.8%	87.0%	87.0%	-2.2p.p.	-2.0p.p.	-2.0p.p.
EBITDA margin	20.8%	24.7%	26.4%	21.4%	25.0%	26.4%	0.6p.p.	0.3p.p.	0.1p.p.
Adj. EBITDA margin	21.3%	24.7%	26.4%	21.8%	25.0%	26.4%	0.5p.p.	0.3p.p.	0.1p.p.
EBIT margin	17.5%	21.7%	23.6%	18.2%	22.0%	23.7%	0.6p.p.	0.3p.p.	0.1p.p.
Adj. EBIT margin	18.1%	21.8%	23.6%	18.6%	22.1%	23.7%	0.5p.p.	0.3p.p.	0.1p.p.

Source: ABG Sundal Collier.

The detailed estimates below represent a breakdown of the company's historical financials and estimates by segment:

# Key financials by segment


				Quarte	rlv data					,	Annual data	2	
SEKm	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25e	Q3'25e	Q4'25e	FY2023	FY2024	FY2025e	FY2026e	FY2027e
Segment sales													
Imaging IT solutions	519	691	601	741	640	660	654	823	2,079	2,552	2,778	3,307	3,739
Total growth y-o-y	19%	37%	19%	17%	23%	-4%	9%	11%	20%	23%	9%	19%	13%
Total growth q-o-q	-18%	33%	-13%	23%	-14%	3%	-1%	26%	n.a.	n.a.	n.a.	n.a.	n.a.
Secure communication	56	83	84	144	78	85	90	100	234	367	353	370	390
Total growth y-o-y	35%	62%	32%	85%	38%	2%	8%	-31%	27%	57%	-4%	5%	5%
Total growth q-o-q	-28%	47%	1%	73%	-46%	10%	6%	11%	n.a.	n.a.	n.a.	n.a.	n.a.
Business Innovation	17	25	23	26	18	26	27	30	74	90	101	114	128
Total growth y-o-y	31%	56%	0%	14%	5%	6%	18%	17%	11%	22%	12%	13%	12%
Total growth q-o-q	-26%	47%	-7%	12%	-32%	48%	4%	11%	n.a.	n.a.	n.a.	n.a.	n.a.
Other operations	35	43	44	43	47	40	40	40	125	165	167	160	160
Total growth y-o-y	30%	33%	40%	27%	37%	-7%	-9%	-8%	26%	32%	1%	-4%	0%
Total growth q-o-q	1%	24%	3%	-2%	9%	-15%	0%	0%	n.a.	n.a.	n.a.	n.a.	n.a.
Group eliminations	-43	-54	-58	-56	-59	-55	-55	-55	-161	-210	-224	-220	-220
Total	584	788	694	898	724	756	756	938	2,351	2,964	3,175	3,731	4,197
Total growth y-o-y	21%	40%	20%	24%	24%	-4%	9%	4%	21%	26%	7%	18%	12%
Total growth q-o-q	-19%	35%	-12%	29%	-19%	4%	0%	24%	n.a.	n.a.	n.a.	n.a.	n.a.
Seament EBIT													
Imaging IT solutions	74	168	67	191	95	132	124	206	462	500	557	803	1,006
Margin	14%	24%	11%	26%	15%	20%	19%	25%	22%	20%	20%	24%	27%
Total growth y-o-y	-8%	53%	-25%	4%	28%	-22%	86%	8%	19%	15%	12%	42%	21%
Total growth g-o-g	-59%	127%	-60%	185%	-50%	39%	-6%	66%	n.a.	n.a.	n.a.	n.a.	n.a.
Secure communication	3	10	9	38	10	9	10	11	19	60	40	48	51
Margin	5%	11%	11%	27%	13%	11%	11%	11%	8%	16%	11%	13%	13%
Total growth v-o-v	n.m.	n.m.	11%	123%	288%	-2%	5%	-71%	n.m.	211%	-33%	19%	5%
Total growth g-o-g	-85%	265%	-1%	307%	-74%	-7%	6%	11%	n.a.	n.a.	n.a.	n.a.	n.a.
Business Innovation	-1	6	4	9	0	6	7	7	10	17	20	32	42
Margin	-6%	22%	17%	34%	-2%	23%	26%	23%	14%	19%	20%	28%	33%
Total growth y-o-y	n.m.	817%	-22%	34%	n.m.	9%	75%	-20%	70%	65%	15%	62%	31%
Total growth g-o-g	n.m.	n.m.	-27%	118%	n.m.	n.m.	17%	0%	n.a.	n.a.	n.a.	n.a.	n.a.
Other operations	-7	-7	-6	-40	-9	-29	-31	37	-36	-59	-33	-45	-87
Margin	-19%	-15%	-13%	-92%	-19%	-73%	-78%	92%	-29%	-36%	-20%	-28%	-54%
Total growth y-o-y	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total growth g-o-g	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.a.	n.a.	n.a.	n.a.	n.a.
Total	69	177	74	197	100	118	110	260	456	518	589	837	1,012
Margin	12%	22%	11%	22%	14%	16%	15%	28%	19%	17%	19%	22%	24%
Total growth y-o-y	8%	64%	-15%	0%	44%	-33%	48%	32%	19%	14%	14%	42%	21%
Total growth g-o-g	-65%	155%	-58%	166%	-49%	18%	-7%	136%	n.a.	n.a.	n.a.	n.a.	n.a.

Source: ABG Sundal Collier, Company data.

### **Run-rate earnings**

We illustrate what the company's earnings would look like had the earnings embedded in the announced contracts that are won been recognised up-front, rather than in two to three years when ramp-ups are finished. We start with our NTM estimate and then add earnings that will not be recognised for a couple of years, but that should be credited given that Sectra has already taken costs up-front (i.e. investments). This serves to illustrate the difference between NTM earnings (based on accounting rules) and the NTM run-rate earnings (as if earnings are credited immediately).

#### Illustrative earnings bridge\*



Source: ABG Sundal Collier.

Footnote: (\*) Note that this differs from our official estimates and only serves to show what earnings would look like if revenues were recognised up-front.

Below, we present our estimates vs. Bloomberg consensus figures:

ABGSC vs. Bloomberg consensus deviation table


	Last	ABGSC		BBG&FS			ABGSC		Blo	omberg (E	BBG)		Devi		
	year	est.	у-о-у	cons.	у-о-у		estimates		consensus			vs.	. Bloomber	g consen	sus
SEKm	Q2'24	Q2'25e	growth	Q2'25e	growth	FY2025e	FY2026e	FY2027e	FY2025e	FY2026e	FY2027e	Q2'25e	FY2025e	FY2026e	FY2027e
Group figures															
Contracted order bookings	503	750	49%	n.a.	n.a.	2,965	4,150	5,350	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Net sales	788	756	-4%	810	3%	3,175	3,731	4,197	3,513	4,043	4,194	-7%	-10%	-8%	0%
y-o-y growth	40%	-4%	-44pp	3%	-37pp	7%	18%	12%	19%	15%	4%	-7pp	-11pp	2pp	9рр
Organic growth	36%	-1%	-37pp	n.a.	n.a.	8%	18%	12%	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBIT	177	118	-33%	147	-17%	589	837	1,012	656	828	932	-20%	-10%	1%	9%
Margin	22%	15%	-7pp	18%	-4pp	18%	22%	24%	19%	20%	22%	-Зрр	-1pp	2pp	1pp
Adj. EBIT	169	129	-24%	n.a.	n.a.	601	840	1,012	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Margin	21%	17%	-4pp	n.a.	n.a.	19%	22%	24%	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Pre-tax profit	190	123	-35%	150	-21%	608	874	1,065	667	847	961	-18%	-9%	3%	11%
Net profit	151	97	-35%	127	-16%	481	690	841	468	668	767	-23%	3%	3%	10%
EPS	0.78	0.51	-35%	0.51	-35%	2.49	3.58	4.37	2.72	3.47	3.98	-1%	-8%	3%	10%
Segment figures															
Imaging IT solutions															
Sales	691	660	-4%	714	3%	2,778	3,307	3,739	n.a.	n.a.	n.a.	-8%	n.a.	n.a.	n.a.
EBIT	168	132	-22%	160	-5%	557	803	1,006	n.a.	n.a.	n.a.	-17%	n.a.	n.a.	n.a.
Secure communication															
Sales	83	85	2%	96	16%	353	370	390	n.a.	n.a.	n.a.	-11%	n.a.	n.a.	n.a.
EBIT	10	9	-2%	13	37%	40	48	51	n.a.	n.a.	n.a.	-28%	n.a.	n.a.	n.a.
Business Innovation															
Sales	25	26	6%	26	6%	101	114	128	n.a.	n.a.	n.a.	0%	n.a.	n.a.	n.a.
EBIT	6	6	9%	6	9%	20	32	42	n.a.	n.a.	n.a.	0%	n.a.	n.a.	n.a.
Other ops. & Group elim.															
Sales	-11	-15	n.m.	n.a.	n.m.	-56	-60	-60	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBIT	-7	-29	n.m.	n.a.	n.m.	-33	<del>-</del> 45	-87	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Revenue type															
Recurring revenue	430	500	16%	n.a.	n.a.	2,040	2,400	2,770	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
o/w cloud recurring rev.	93	133	43%	n.a.	n.a.	568	803	1,103	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Non-recurring revenue	358	257	-28%	n.a.	n.a.	1,135	1,331	1,427	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Source: ABG Sundal Collier, Company data, Bloomberg.

# Hiring activity

Data from LinkedIn show that the company is continuing to hire at a rapid pace ( $\sim$ 7% FTE growth y-o-y). Currently, Sectra is hiring additional FTEs at an annual run-rate of  $\sim$ 100.


#### Sectra associated members on LinkedIn



Source: ABG Sundal Collier, LinkedIn (dated September 6, 2024).

We have performed a simple analysis: we plot LTM order bookings against LTM hiring for each quarter, with a one-year lag for the latter. The result shows that hiring has historically predicted order bookings relatively well. In the future, we expect this model to show larger order bookings per FTE hired, because Sectra One Cloud contracts in North America are generally larger. With an annual run-rate hiring pace of ~100 FTEs, our model would suggest order bookings of ~SEK 4-4.5bn. This is significantly higher than our estimate of ~SEK 3bn for the coming year.

# Hiring activity predicts order bookings



Source: ABG Sundal Collier, Company data.

# Peer overview

We have selected two peer groups for Sectra: (i) Imaging IT peers and (ii) Nordic high-growth & high-margin peers. We seek to benchmark Sectra against peers with similar business models and Nordic peers that are generally considered successful, high-growth businesses, but that may have somewhat different value drivers.

# **Imaging IT peers**

There are two peers that are both operationally highly similar to Sectra: Pro Medicus and Mach7. Pro Medicus is arguably Sectra's number one competitor and is specialised in radiology and (soon) cardiology imaging, whereas Mach7 is specialised in Vendor Neutral Archiving.

Sectra's top-line growth is slightly lower than that of its Imaging IT peers, but that is due to the timing of the execution of a large contract (which is only included in half of calendar year '25e), as well as to Sectra's secure communications segment, which we assess grows at a slower pace than Imaging IT. Since nearly 100% of Sectra's EBITA is attributable to Imaging IT, it is a slightly better indicator of the Imaging IT segment's growth. At a calendar '24e-'26e EBIT growth rate of 35%, Sectra grows at a somewhat higher pace than Pro Medicus. All else equal, this would imply a faster growth rate in the Imaging IT segment compared to Pro Medicus – a mechanism that should warrant a slight premium.

Overall, we believe that Sectra should trade at a minor discount to Pro Medicus due to Sectra's lower share of recurring revenues. That said, we assess that the discount should be lower than it currently is.

#### **Imaging IT peers**

Valuation metrics											
		EV/Sales			EV/EBITA			FCFE yiel	d	Sales CAGR	EBIT CAGR
	2024e	2025e	2026e	2024e	2025e	2026e	2024e	2025e	2026e	'24e-'26e	24e- 26e
Imaging IT peers											
Pro Medicus	99x	77x	62x	133x	98x	76x	1%	1%	1%	27%	31%
Mach7 Technologies	4x	3x	3x	n.m.	n.m.	68x	1%	n.m.	2%	20%	-41%
Sectra*	16x	14x	12x	92x	60x	51x	0%	1%	1%	14%	35%
Sectra* (run-rate earnings)	n.m.	n.m.	n.m.	48x	42x	37x	n.m.	n.m.	n.m.	n.m.	n.m.
Peer average	51x	40x	32x	133x	98x	72x	1%	1%	1%	24%	-5%
Peer median	51x	40x	32x	133x	98x	72x	1%	1%	1%	24%	-5%

Source: ABG Sundal Collier, FactSet.

Footnote: Periods denote calendar rather than fiscal years.

# Nordic high-growth & high-margin peers

We also include Nordic peers that are generally considered to have showed strong historical operating performance with top-tier financial profiles. Most, if not all, peers are likely earning margins that could be considered maintainable. However, the discrepancy between reported earnings and unit economics is currently substantial for Sectra, and that is why the company is trading at a meaningful premium to Nordic peers. That said, there are qualitative reasons for why Sectra should trade at a premium. In our opinion, those factors include: four growth pillars (price, volume, Licence-to-SaaS conversion and upselling), global scalability, and lower regulatory risks relative to some peers.

For clarity, Fortnox and Hemnet constitute core Nordic peers for Sectra.

# Sectra

# Nordic high growth & high margin peers


Valuation metrics											
		EV/Sales			EV/EBITA			FCFE yield	t	Sales CAGR	EBITA CAGR
	2024e	2025e	2026e	2024e	2025e	2026e	2024e	2025e	2026e	24e-26e	'24e-'26e
Nordic high growth & high margin pe	eers										
Vitec Software Group	7x	6x	6x	21x	19x	17x	2%	2%	3%	8%	10%
Fortnox	17x	13x	11x	37x	28x	22x	2%	2%	3%	24%	31%
Hemnet Group	25x	20x	17x	48x	36x	29x	2%	2%	3%	23%	29%
ChemoMetec	16x	15x	13x	39x	34x	29x	1%	2%	2%	14%	16%
CellaVision	8x	7x	6x	31x	25x	21x	2%	2%	3%	14%	21%
Sectra*	16x	14x	12x	92x	60x	51x	0%	1%	1%	14%	35%
Sectra* (run-rate earnings)	n.m.	n.m.	n.m.	48x	42x	37x	n.m.	n.m.	n.m.	n.m.	n.m.
Core peer average	21x	17x	14x	43x	32x	25x	2%	2%	3%	24%	30%
Core peer median	21x	17x	14x	43x	32x	25x	2%	2%	3%	24%	30%

Source: ABG Sundal Collier, FactSet.
Footnote: (\*) ABGSC estimates.

# **Valuation**

Sectra is trading at a significant discount to its key competitor and peer Pro Medicus, and we argue that the discount should narrow given the two firms' near-identical operating profiles, growth and value drivers. We value Sectra at SEK 300 per share, implying nearly 20% upside, based on both our sum-of-the-parts analyses on reported and maintainable earnings, and a discounted cash flow valuation. On NTM EBIT (as if reported), our TP implies a multiple of ~89x while a normalised/maintainable NTM EBIT implies an NTM EV/EBIT multiple of ~52x.

#### Valuation summary




Source: ABG Sundal Collier.

In comparing Sectra to Pro Medicus, we find that Sectra has traded at an average discount of ~10% in the last 10 years. The discount has widened to ~30% in the last six months. We argue that the similarities between Sectra and Pro Medicus should warrant a closing of the valuation gap. In the context of a maintainable margin of 30-35% rather than a reported margin of 20%, the valuation discrepancy becomes even more significant (and in our view unjustified), as the two companies have near-identical value and growth drivers.

Should the discount to Pro Medicus narrow to the historical average of ~10%, Sectra's share price would be ~SEK 330.


## Sectra vs. Pro Medicus



Source: ABG Sundal Collier, FactSet.

Below, we show the impact of a SaaS transition on the company's valuation multiples. The left-hand graph shows multiples that are based on the company's reporting standards, which leave out revenues from contracts that have a longer ramp-up period. The right-hand graph shows what the multiple would be based on run-rate earnings, which includes the embedded earnings in contracts that are not fully ramped up nor live yet. In the near term, this effect is large, as the discrepancy between FY'25e multiples is large (82x vs. 46x). However, over time, the effect is smoothed out.


# EV/EBIT multiples based on reporting standards\*



Source: ABG Sundal Collier.

Footnote: (\*) Based on the company's revenue recognition standards for recurring revenues being recognised over contract lifetime.

# EV/EBIT multiples on run-rate earnings\*



Source: ABG Sundal Collier.

Footnote: (\*) Considers earnings for contracts that are won but not visible in the P&L due to revenue lag due to revenues being recorded over the contract lifetime in addition to earnings based on Sectra's reporting standards.

Income Statement (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	1,266	1,449	1,661	1,632	1,949	2,351	2,964	3,175	3,731	4,197
COGS	-188	-255	-248	-196	-286	-263	-431	-428	-494	-555
Gross profit	1,079	1,195	1,413	1,436	1,663	2,088	2,532	2,746	3,237	3,641
Other operating items	-775	-877	-1,030	-1,003	-1,198	-1,540	-1,910	-2,054	-2,288	-2,514
EBITDA	304	318	382	433	465	548	622	693	949	1,128
Depreciation and amortisation	-61	-59	-83	-79	-77	-88	-94	-100	-108	-112
of which leasing depreciation	0	0	-22	-28	-32	-32	-29	-28	-28	-28
EBITA	243	259	299	354	387	460	528	593	841	1,016
EO Items	-5	27	-7	-66	24	62	19	-13	-3	0
Impairment and PPA amortisation	-4	-4	-4	-4	-4	-4	-10	-4	-4	-4
EBIT	239	255	295	350	383	456	518	589	837	1,012
Net financial items	10	9	8	-2	11	24	35	19	37	53
Pretax profit	249	264	303	348	395	479	553	608	874	1,065
Tax	-51	-53	-66	-73	-80	-104	-124	-127	-184	-224
Net profit	198	210	237	276	315	375	428	481	690	841
Minority interest	0	0 0	0 0	0 0	0	0	0	0	0 0	0
Net profit to abarahadara			<b>237</b>							
Net profit to shareholders	<b>198</b> 1.04	<b>210</b> 1.10	1.23	<b>276</b> 1.43	<b>315</b> 1.63	<b>375</b> 1.95	<b>428</b> 2.22	<b>481</b> 2.49	<b>690</b> 3.58	<b>841</b> 4.37
EPS	1.04	1.10	1.23	1.43	1.55	1.95	2.22	2.49	3.61	4.38
EPS adj.	-4	21	-5	-53	1.33	49	15	-10	-2	<del>4.30</del>
Total extraordinary items after tax	- <del>4</del> 0	0	-3 -22	-33 -28	-32	-32	-29	-10	-2 -28	-28
Leasing payments Tax rate (%)	20.5	20.2	21.7	20.9	20.2	21.8	22.5	20.9	21.0	21.0
Gross margin (%)	85.2	82.4	85.1	88.0	85.3	88.8	85.4	86.5	86.8	86.8
EBITDA margin (%)	24.0	21.9	23.0	26.5	23.8	23.3	21.0	21.8	25. <i>4</i>	26.9
EBITA margin (%)	19.2	17.9	18.0	21.7	19.9	19.6	17.8	18.7	22.5	24.2
EBIT margin (%)	18.9	17.6	17.8	21.4	19.7	19.4	17.5	18.5	22.4	24.1
Pre-tax margin (%)	19.7	18.2	18.2	21.3	20.2	20.4	18.6	19.1	23.4	25.4
Net margin (%)	15.7	14.5	14.3	16.9	16.2	16.0	14.5	15.1	18.5	20.0
Growth Rates y-o-y	_	-	-	-		-	_	-	-	
Sales growth (%)	11.0	14.4	14.6	-1.7	19.4	20.6	26.1	7.1	17.5	12.5
EBITDA growth (%)	12.2	4.5	20.3	13.3	7.3	17.9	13.6	11.4	37.0	18.8
EBITA growth (%)	18.9	6.6	15.5	18.3	9.4	18.7	14.8	12.3	42.0	20.7
EBIT growth (%)	19.3	6.7	15.8	18.5	9.5	18.8	13.6	13.7	42.3	20.8
Net profit growth (%)	29.8	6.1	12.8	16.1	14.3	19.1	14.2	12.2	43.6	21.9
EPS growth (%)	29.0	5.5	12.3	16.0	14.2	19.1	14.2	12.2	43.6	21.9
Profitability	-	-	-	-	-	-	-	-	-	-
ROE (%)	32.6	30.3	30.7	32.2	31.9	31.5	29.9	28.2	33.5	32.9
ROE adj. (%)	34.0	27.8	31.9	38.8	30.3	27.8	29.6	29.0	33.8	33.0
ROCE (%)	40.3	37.5	37.1	37.2	37.2	37.9	37.0	34.8	41.4	40.8
ROCE adj. (%)	41.8	34.3	38.4	44.8	35.4	33.3	36.4	35.7	41.7	41.0
ROIC (%)	76.0	92.3	74.9	72.9	114.1	151.5	85.7	62.0	73.9	83.0
ROIC adj. (%)	77.7	82.7	76.6	86.5	107.1	130.9	82.6	63.3	74.1	83.0
Adj. earnings numbers	-	-	-	-	-	-		-		
EBITDA adj.	310	291	389	500	441	485	603	705	952	1,128
EBITDA adj. margin (%)	24.4	20.1	23.4	30.6	22.6	20.6	20.3	22.2	25.5	26.9
EBITDA lease adj.	310	291	367	472	409	453	574	677	924	1,100
EBITDA lease adj. margin (%)	24.4	20.1	22.1	28.9	21.0	19.3	19.4	21.3	24.8	26.2
EBITA adj.	249	232	306	420	364	397	509	605	844	1,016
EBITA adj. margin (%)	19.6 245	16.0 228	<i>18.4</i> 302	25.8 416	18.7 360	16.9 393	17.2 505	<i>19.1</i> 601	22.6 840	24.2
EBIT adj.										1,012
EBIT adj. margin (%)	19.3 259	<i>15.8</i> 241	<i>18.2</i> 314	25.5 419	18.4 375	<i>16.7</i> 421	17.0 544	18.9 625	22.5 880	<i>24.1</i> 1,069
Pretax profit Adj.	207	193	247	332	300	330	424	495	696	845
Net profit Adj.  Net profit to shareholders adj.	207	193	247	332	300	330	424	495	696	845
Net adj. margin (%)	16.3	13.3	14.9	20.3	15.4	14.0	14.3	15.6	18.7	20.1
Source: ABG Sundal Collier, Company		, 0.0	1 1.3	20.0	, , , ,	7 7.0	, ,	70.0	10.1	
Cash Flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	304	318	382	433	465	548	622	693	949	1,128
Net financial items	10	9	8	-2	11	24	35	19	37	53
Paid tax	-51	-53	-66	-73	-80	-104	-124	-127	-184	-224
Non-cash items	-107	-13	37	-12	1	76	12	3	0	0
Cash flow before change in WC	157	260	362	347	397	543	545	588 171	802	957
Change in working capital	51 	-8	-34	25	220	-102	-218	-171	-33	-36

Cash Flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Operating cash flow	208	253	327	372	617	440	326	417	770	922
Capex tangible fixed assets	-15	-10	-33	-20	-30	-37	-179	-54	-36	-36
Capex intangible fixed assets	-8	-25	-46	-46	-38	-176	48	-70	-80	-84
Acquisitions and Disposals	-2	-0	-3	-2	0	0	0	0	0	0
Free cash flow	183	217	246	303	549	228	196	293	654	802
Dividend paid	-171	-172	-173	-173	-173	-193	-212	-212	-250	-289
Share issues and buybacks	0	0	0	0	0	0	0	0	0	0
Leasing liability amortisation	0	0	-21	-22	-24	-27	-10	-25	-28	-28
Other non-cash items	225	20	-117	5	44	52	-49	-13	0	-0
Balance Sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Goodwill	55	57	49	46	50	52	49	49	49	49
Other intangible assets	133	126	144	161	168	185	214	239	271	307
Tangible fixed assets	43	40	66	56	62	75	227	228	228	224
Right-of-use asset	0	0	84	73	65	85	35	69	69	69
Total other fixed assets	176	176	166	144	177	132	164	174	174	174
Fixed assets	408	399	510	480	522	528	689	758	790	822
Inventories	30	41	33	25	24	37	37	48	53	58
Receivables	253	259	276	236	340	386	572	573	633	697
Other current assets	313	284	348	456	497	840	1,109	1,375	1,518	1,673
Cash and liquid assets	282	332	345	455	809	945	805	859	1,234	1,719
Total assets	1,286	1,315	1,512	1,652	2,192	2,737	3,211	3,613	4,228	4,970
Shareholders equity	661	728	817	896	1,081	1,297	1,570	1,843	2,282	2,835
Minority	0	0	0	0	0	0	0	0	0	0
Total equity	661	728	817	896	1,081	1,297	1,570	1,843	2,282	2,835
Long-term debt	0	0	0	0	0	0	0	0	0	0
Pension debt	0	0	0	0	0	0	0	0	0	0
Convertible debt	0	0	0	0	0	0	0	0	0	0
Leasing liability	0	0	81	71	62	82	32	46	46	46
Total other long-term liabilities	49	28	25	5	9	18	33	40	40	40
Short-term debt	7	9	0	6	3	2	3	3	3	3
Accounts payable	46	55	0	0	0	0	0	0	0	0
Other current liabilities	524	494	588	674	1,037	1,338	1,574	1,680	1,856	2,045
Total liabilities and equity	1,286	1,315	1,512	1,652	2,192	2,737	3,211	3,613	4,228	4,970
Net IB debt	-448	-493	-426	-518	-916	-987	-925	-975	-1,350	-1,835
Net IB debt excl. pension debt	-448	-493	-426	-518	-916	-987	-925	-975	-1,350	-1,835
Net IB debt excl. leasing	-448	-493	-507	-589	-978	-1,069	-957	-1,021	-1,396	-1,881
Capital employed	668	737	898	973	1,146	1,381	1,604	1,892	2,332	2,884
Capital invested	213	235	391	377	165	310	644	867	932	1,000
Working capital	26	34	68	43	-177	-75	144	315	348	383
EV breakdown	40.070	40.077	40.470	40.407	40.000	40.007	40.007	40.007	40.007	40.007
Market cap. diluted (m)	48,679	48,977	49,172	49,197	49,206	49,207	49,207	49,207	49,207	49,207
Net IB debt adj.	-448	-493	-426	-518	-916	-987	-925	-975	-1,350	-1,835
Market value of minority	0	0	0	0	0	0	0	0	0	0
Reversal of shares and participations	0	0	0	0	0	0	0	0	0	0
Reversal of conv. debt assumed	_	_	_	_	_	_		_	_	_
equity										
EV	48,231	48,483	48,746	48,679	48,290	48,221	48,282	48,232	47,857	47,372
Total assets turnover (%)	103.4	111.4	117.5	103.2	101.4	95.4	99.7	93.1	95.2	91.3
Working capital/sales (%)	4.1	2.1	3.1	3.4	-3.4	-5.3	1.2	7.2	8.9	8.7
Financial risk and debt service	-	-	-	-	-	-	-	-	-	-
Net debt/equity (%)	-67.7	-67.8	-52.1	-57.9	-84.8	-76.1	-59.0	-52.9	-59.2	-64.7
Net debt / market cap (%)	-0.9	-1.0	-0.9	-1.1	-1.9	-2.0	-1.9	-2.0	-2.7	-3.7
Equity ratio (%)	51.4	55.4	54.1	54.2	49.3	47.4	48.9	51.0	54.0	57.0
Net IB debt adj. / equity (%)	-67.7	-67.8	-52.1	-57.9	-84.8	-76.1	-59.0	-52.9	-59.2	-64.7
Current ratio	1.52	1.64	1.70	1.72	1.60	1.65	1.60	1.70	1.85	2.02
EBITDA/net interest	29.9	37.2	49.7	236.7	41.8	23.1	17.8	35.7	26.0	21.1
Net IB debt/EBITDA (x)	-1.5	-1.6	-1.1	-1.2	-2.0	-1.8	-1.5	-1.4	-1.4	-1.6
Net IB debt/EBITDA lease adj. (x)	-1.4	-1.7	-1.4	-1.2	-2.4	-2.4	-1.7	-1.5	-1.5	-1.7
Interest coverage										
Source: ABG Sundal Collier, Company	Data									
Share Data (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Actual shares outstanding	38	38	39	39	193	193	193	193	193	193
Actual shares outstanding (avg)	38	38	39	39	193	193	193	193	193	193
. Islaal shalloo salstanding (avg)							.00			.00

Share Data (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
All additional shares	0	0	0	0	154	0	0	0	0	0
Issue month	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Assumed dil. of shares from conv.	0	0	0	0	0	0	0	0	0	0
As. dil. of shares from conv. (avg)	0	0	0	0	0	0	0	0	0	0
Conv. debt not assumed as equity	0	0	0	0	0	0	0	0	0	0
No. of warrants	0	0	0	0	0	0	0	0	0	0
Market value per warrant	0	0	0	0	0	0	0	0	0	0
Dilution from warrants	0	0	0	0	0	0	0	0	0	0
Issue factor	5.0	5.0	5.0	5.0	1.0	1.0	1.0	1.0	1.0	1.0
Actual dividend per share	0.90	0.90	0.90	0.90	1.00	1.10	1.10	1.30	1.50	1.60
Reported earnings per share	5.20	5.49	6.16	7.15	1.63	1.95	2.22	2.49	3.58	4.37

Source: ABG Sundal Collier, Company Data

Valuation and Ratios (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Shares outstanding adj.	191	192	193	193	193	193	193	193	193	193
Diluted shares adj.	191	192	193	193	193	193	193	193	193	193
EPS	1.04	1.10	1.23	1.43	1.63	1.95	2.22	2.49	3.58	4.37
Dividend per share	0.18	0.18	0.18	0.18	1.00	1.10	1.10	1.30	1.50	1.60
EPS adj.	1.08	1.00	1.28	1.72	1.55	1.71	2.19	2.56	3.61	4.38
BVPS	3.47	3.80	4.24	4.65	5.61	6.73	8.15	9.56	11.85	14.71
BVPS adj.	2.48	2.84	3.24	3.57	4.48	5.50	6.79	8.07	10.19	12.87
Net IB debt/share	-2.35	-2.57	-2.21	-2.69	-4.76	-5.12	-4.80	-5.06	-7.01	-9.52
Share price	255.40	255.40	255.40	255.40	255.40	255.40	255.40	255.40	255.40	255.40
Market cap. (m)	48,679	48,977	49,172	49,197	49,206	49,207	49,207	49,207	49,207	49,207
Valuation	-	-	-	-	-	-	-	-	-	-
P/E (x)	245.5	232.7	207.2	178.6	156.3	131.2	114.9	102.4	71.3	58.5
EV/sales (x)	38.08	33.46	29.35	29.82	24.77	20.51	16.29	15.19	12.83	11.29
EV/EBITDA (x)	158.6	152.5	127.5	112.4	103.9	88.1	77.6	69.6	50.4	42.0
EV/EBITA (x)	198.4	187.1	162.8	137.5	124.7	104.9	91.5	81.4	56.9	46.6
EV/EBIT (x)	201.7	190.1	165.0	139.1	126.0	105.8	93.3	81.9	57.2	46.8
Dividend yield (%)	0.1	0.1	0.1	0.1	0.4	0.4	0.4	0.5	0.6	0.6
FCF yield (%)	0.4	0.4	0.5	0.6	1.1	0.5	0.4	0.6	1.3	1.6
Le. adj. FCF yld. (%)	0.4	0.4	0.5	0.6	1.1	0.4	0.4	0.5	1.3	1.6
P/BVPS (x)	73.65	67.28	60.17	54.93	45.53	37.95	31.35	26.71	21.56	17.36
P/BVPS adj. (x)	80.37	72.98	64.02	57.92	47.73	39.52	32.36	27.43	22.03	17.66
P/E adj. (x)	236.6	254.9	200.0	148.5	164.6	149.4	116.7	99.6	70.8	58.3
EV/EBITDA adj. (x)	155.8	166.6	125.2	97.4	109.6	99.4	80.1	68.4	50.3	42.0
EV/EBITA adj. (x)	194.1	208.8	159.2	115.8	132.8	121.4	94.9	79.7	56.7	46.6
EV/EBIT adj. (x)	197.2	212.4	161.3	116.9	134.3	122.6	95.7	80.2	57.0	46.8
EV/CE (x)	72.2	65.8	54.3	50.0	42.1	34.9	30.1	25.5	20.5	16.4
Investment ratios	-	-	-	-	-	-	-	-	-	-
Capex/sales (%)	1.8	2.4	4.7	4.1	3.5	9.1	4.4	3.9	3.1	2.9
Capex/depreciation	0.4	0.6	1.3	1.3	1.5	3.8	2.0	1.7	1.5	1.4
Capex tangibles / tangible fixed assets	34.9	24.2	49.7	36.6	48.6	49.7	78.6	23.8	15.8	16.1
Capex intangibles / definite intangibles										
Depreciation on intang / def. intang										
Depreciation on tangibles / tangibles	81.11	66.60	39.35	27.15	14.89	26.74	11.64	13.66	15.79	17.86

Source: ABG Sundal Collier, Company Data

# **Analyst Certification**

We, ABGSC IT Research, Nikola Kalanoski and Daniel Thorsson, analyst(s) with ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited (hereinafter collectively referred to as "ABG Sundal Collier"), and the author(s) of this report, certify that not withstanding the existence of any such potential conflicts of interests referred to below, the views expressed in this report accurately reflect my/our personal view about the companies and securities covered in this report. I/We further certify that I/We has/have not been, nor am/are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

This report is produced by ABG Sundal Collier, which may cover companies either in accordance with legal requirements designed to promote the independence of investment research ("independent research") or as commissioned research. Commissioned research is paid for by the subject company. As such, commissioned research is deemed to constitute an acceptable minor non-monetary benefit (i.e., not investment research) as defined in MiFID II.

# Stock ratings distribution

ABG Sundal Collier Ratings and Investment Banking by 9/8/2024

	Research Coverage	Investment Banking Clients (IBC)			
	% of	% of	% of		
Total of Rating	Total Rating	Total IBC	Total Rating by Type		
BUY	65.03%	17%	7.14%		
HOLD	30.60%	4%	3.57%		
SELL	3.83%	1%	7.14%		

IBC: Companies in respect of which ABG SC or an affiliate has received compensation for investment banking services within the past 12 months.

# Analyst stock ratings definitions

**BUY =** We expect this stock's total return to exceed the market's expected total return by 5% or more over the next six months.

**HOLD** = We expect this stock's total return to be in line with the market's expected total return within a range of 4% over the next six months.

**SELL** = We expect this stock's total return to underperform the market's expected total return by 5% or more over the next six months.

# **Analyst valuation methods**

When setting the individual ratings for investment research ("independent research"), ABG Sundal Collier assumes that a normal total absolute return (including dividends) for the market is 8% per annum, or 4% on a 6-month basis. Therefore, when we rate a stock a BUY, we expect an absolute return of 9% or better over six months. Volatility and low trading volumes mean that we have a wider range for expected returns on small cap stocks than for large caps.

ABG Sundal Collier's analysts publish price targets for independent research and may publish valuation ranges for commissioned research. These price targets or valuation ranges rely on various valuation methods. One of the most frequently used methods is the valuation of a company by calculation of that company's discounted cash flow (DCF). Another valuation method is the analysis of a company's return on capital employed relative to its cost of capital. Finally, the analysts may analyse various valuation multiples (e.g., the P/E multiples and the EV/EBITDA multiples) relative to global industry peers. In special cases, particularly for property companies and investment companies, the ratio of price to net asset value is considered. Price targets and valuation ranges are changed when earnings and cash flow forecasts are changed. They may also be changed when the underlying value of a company's assets changes (in the cases of investment companies, real estate companies or insurance companies) or when factors impacting the required rate of return change.

# **Expected updates**

ABGSC has no fixed schedule for updating its research reports. Unless expressly stated otherwise, ABGSC expects (but does not undertake) to issue updates when considered necessary by the research department, for example following the publication of new figures or forecasts by a company or in the event of any material news on a company or its industry.

# Stock price, company ratings and target price history

Company:SectraCurrency:SEKCurrent Recommandation:BUYDate:5/9/2024Current Target price:300.0

Current Share price: 255.40



# **Important Company Specific Disclosure**

The following disclosures relate to the relationship between ABG Sundal Collier and its affiliates and the companies covered by ABG Sundal Collier referred to in this research report.

Unless disclosed in this section, neither ABG Sundal Collier nor any of their affiliated or associated companies and their directors, officers, representatives, and employees have any required regulatory disclosures to make in relation to an ownership position for the analyst(s) and members of the analyst's household, ownership by ABG Sundal Collier and/or its affiliates, ownership in ABG Sundal Collier Holding ASA by the company(ies) to whom the recommendation(s) refer(s) to, liquidity provision/market making agreement, managed or co-managed public offerings, compensation for provision of certain services, directorship of the analyst, or a member of the analyst's household, or in relation to any contractual obligations to the issuance of this research report.

ABG Sundal Collier is not aware of any other actual, material conflicts of interest of the analyst or ABG Sundal Collier of which the analyst knows or has reason to know at the time of the publication of this report.

Production of recommendation: 9/8/2024 21:08.

All prices are as of market close on 5 September, 2024 unless otherwise noted.

For full details of recommendation and target price history for the subject company, please see company page on Research Web.

For details of recommendations and target prices for ABG Sundal Collier coverage universe, please see coverage page on ABG Sundal Collier's Research Web.

#### **Disclaimer**

This report has been prepared by ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier ABG Sundal Collier Limited and any of their directors, officers, representatives and employees (hereinafter collectively referred to as "ABG Sundal Collier"). This report is not a product of any other affiliated or associated companies of any of the above entities.

This report is provided solely for the information and use of professional investors, who are expected to make their own investment decisions without undue reliance on this report. The information contained herein does not apply to, and should not be relied upon by, retail clients. This report is for distribution only under such circumstances as may be permitted by applicable law. Research reports prepared by ABG Sundal Collier are for information purposes only. The recommendation(s) in this report is (are) has/ have no regard to specific investment objectives and the financial situation or needs of any specific recipient. ABG Sundal Collier and/or its affiliates accepts no liability whatsoever for any losses arising from any use of this report or its contents. This report is not to be used or considered as an offer to sell, or a solicitation of an offer to buy. The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but ABG Sundal Collier and/or its affiliates make no representation as to its accuracy or completeness and it should not be relied upon as such. All opinions and estimates herein reflect the judgment of ABG Sundal Collier on the date of this report and are subject to change without notice. Past performance is not indicative of future results.

The compensation of our research analysts is determined exclusively by research management and senior management, but not including investment banking management. Compensation is not based on specific investment banking revenues, however, it is

determined from the profitability of the ABG Sundal Collier group, which includes earnings from investment banking operations and other business. Investors should assume that ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge and/or ABG Sundal Collier AB is seeking or will seek investment banking or other business relationships with the companies in this report.

The research analyst(s) responsible for the preparation of this report may interact with trading desk and sales personnel and other departments for the purpose of gathering, synthesizing and interpreting market information. From time to time, ABG Sundal Collier and/or its affiliates and any shareholders, directors, officers, or employees thereof may (I) have a position in, or otherwise be interested in, any securities directly or indirectly connected to the subject of this report, or (II) perform investment banking or other services for, or solicit investment banking or other services from, a company mentioned in this report. ABG Sundal Collier and/or its affiliates rely on information barriers to control the flow of information contained in one or more areas of ABG Sundal Collier, into other areas, units, groups or affiliates of ABG Sundal Collier.

Norway: ABG Sundal Collier ASA is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet)

Denmark: ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet) and the Danish Financial Supervisory Authority (Finanstilsynet)

Sweden: ABG Sundal Collier AB is regulated by the Swedish Financial Supervisory Authority (Finansinspektionen)

UK: This report is a communication made, or approved for communication in the UK, by ABG Sundal Collier Limited, authorised and regulated by the Financial Conduct Authority in the conduct of its business.

US: This report is being distributed in the United States (U.S.) in accordance with FINRA Rule 1220 by ABG Sundal Collier Inc., an SEC registered broker-dealer and a FINRA/SIPC member which accepts responsibility for its content and its compliance with FINRA Rule 2241. Research reports distributed in the U.S. are intended solely for "major U.S. institutional investors," and "U.S. institutional investors" as defined under Rule 15a-6 of the Securities Exchange Act of 1934 and any related interpretive guidance and no-action letters issued by the Staff of the U.S. Securities and Exchange Commission ("SEC") collectively ("SEC Rule 15a-6"). Each major U.S. institutional investor and U.S. institutional investor that receives a copy of this research report, by its acceptance of such report, represents that it agrees that it will not distribute this research report to any other person. This communication is only intended for major U.S. institutional investors and U.S. institutional investors. Any person which is not a major U.S. institutional investor, or a U.S. institutional investor as covered by SEC Rule 15a-6 must not rely on this communication. The delivery of this research report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. Any major U.S. institutional investor or U.S. institutional investor receiving this report which wishes to effect transactions in any securities referred to herein should contact ABG Sundal Collier Inc., on request.

Singapore: This report is distributed in Singapore by ABG Sundal Collier Pte. Ltd, which is not licensed under the Financial Advisors Act (Chapter 110 of Singapore). In Singapore, this report may only be distributed to institutional investors as defined in Section 4A(1)(c) of the Securities and Futures Act (Chapter 289 of Singapore) ("SFA"), and should not be circulated to any other person in Singapore.

Canada: This report is being distributed by ABG Sundal Collier ASA in Canada pursuant to section 8.25 of National Instrument 31-103 or an equivalent provision and has not been tailored to the needs of any specific investor in Canada. The information contained in this report is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering or an offer to sell the securities described herein, in Canada or any province or territory thereof. No securities commission or similar regulatory authority in Canada has reviewed or considered this report, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Under no circumstances is this report to be construed as an offer to sell such securities or as a solicitation of an offer to buy such securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada may only be made in accordance with applicable securities laws and only by a dealer properly registered under such securities laws, or alternatively, pursuant to an applicable dealer registration exemption, in the Canadian jurisdiction in which such offer or sale is made.

This report may not be reproduced, distributed, or published by any recipient for any purpose whatsoever without the prior written express permission of ABG Sundal Collier.

Additional information available upon request. If reference is made in this report to other companies and ABG Sundal Collier provides research coverage for those companies, details regarding disclosures may be found on our website <a href="https://www.abgsc.com">www.abgsc.com</a>.

© Copyright 2024 ABG Sundal Collier ASA

Norway Denmark **United Kingdom** USA Sweden Germany Forbindelsesvej 12, 140 Broadway, Suite 4604 Schillerstrasse 2, 5. OG Ruseløkkveien 26, 8th floor Regeringsgatan 25, 8th 10 Paternoster Row, 5th 10 Collyer Quay 0251 Oslo floor 2100 Copenhagen floor New York, NY 10005 60313 Frankfurt Ocean Financial Center 111 53 Stockholm London EC4M 7EJ #40-07, Singapore 049315 Tel: +47 22 01 60 00 Sweden Tel: +45 35 46 61 00 UK Tel +49 69 96 86 96 0 Tel. +1 212 605 3800 Tel +65 6808 6082 Tel: +46 8 566 286 00 Tel: +44 20 7905 5600 Fax: +47 22 01 60 60 Fax: +45 35 46 61 10 Fax. +1 212 605 3801 Fax +49 69 96 86 96 99 Fax: +46 8 566 286 01 Fax: +44 20 7905 5601